Works by Fujiwara, Keiichi

Results: 219
    1
    2
    3
    4
    5

    Twenty-four weeks of interferon α-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1.

    Published in:
    Liver International, 2006, v. 26, n. 5, p. 520, doi. 10.1111/j.1478-3231.2006.01263.x
    By:
    • Fujiwara, Keiichi;
    • Yokosuka, Osamu;
    • Komine, Fumihiko;
    • Moriyama, Mitsuhiko;
    • Kato, Naoya;
    • Yoshida, Haruhiko;
    • Tanaka, Naohide;
    • Imazeki, Fumio;
    • Shiratori, Yasushi;
    • Arakawa, Yasuyuki;
    • Omata, Masao
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12

    Occurrence of Hepatocellular Carcinoma Was Not a Rare Event during and Immediately after Antiviral Treatment in Japanese HCV-Positive Patients.

    Published in:
    Oncology, 2011, v. 80, n. 5/6, p. 366, doi. 10.1159/000330549
    By:
    • Kanda, Tatsuo;
    • Imazeki, Fumio;
    • Mikami, Shigeru;
    • Kato, Keizo;
    • Shimada, Noritomo;
    • Yonemitsu, Yutaka;
    • Miyauchi, Tomoo;
    • Arai, Makoto;
    • Fujiwara, Keiichi;
    • Tsubota, Akihito;
    • Takada, Nobuo;
    • Nishino, Takayoshi;
    • Takashi, Motohide;
    • Sugiura, Nobuyuki;
    • Kimura, Michio;
    • Fukai, Kenichi;
    • Yokosuka, Osamu
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23

    Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)

    Published in:
    Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221116603
    By:
    • Tanzawa, Shigeru;
    • Makiguchi, Tomonori;
    • Tasaka, Sadatomo;
    • Inaba, Megumi;
    • Ochiai, Ryosuke;
    • Nakamura, Junya;
    • Inoue, Koji;
    • Kishikawa, Takayuki;
    • Nakashima, Masanao;
    • Fujiwara, Keiichi;
    • Kohyama, Tadashi;
    • Ishida, Hiroo;
    • Kuyama, Shoichi;
    • Miyazawa, Naoki;
    • Nakamura, Tomomi;
    • Miyawaki, Hiroshi;
    • Oda, Naohiro;
    • Ishikawa, Nobuhisa;
    • Morinaga, Ryotaro;
    • Kusaka, Kei
    Publication type:
    Article
    24

    A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).

    Published in:
    Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/1758835921998588
    By:
    • Tanzawa, Shigeru;
    • Ushijima, Sunao;
    • Shibata, Kazuhiko;
    • Shibayama, Takuo;
    • Bessho, Akihiro;
    • Kaira, Kyoichi;
    • Misumi, Toshihiro;
    • Shiraishi, Kenshiro;
    • Matsutani, Noriyuki;
    • Tanaka, Hisashi;
    • Inaba, Megumi;
    • Haruyama, Terunobu;
    • Nakamura, Junya;
    • Kishikawa, Takayuki;
    • Nakashima, Masanao;
    • Iwasa, Keiichi;
    • Fujiwara, Keiichi;
    • Kohyama, Tadashi;
    • Kuyama, Shoichi;
    • Miyazawa, Naoki
    Publication type:
    Article
    25

    A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).

    Published in:
    Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/1758835921998588
    By:
    • Tanzawa, Shigeru;
    • Ushijima, Sunao;
    • Shibata, Kazuhiko;
    • Shibayama, Takuo;
    • Bessho, Akihiro;
    • Kaira, Kyoichi;
    • Misumi, Toshihiro;
    • Shiraishi, Kenshiro;
    • Matsutani, Noriyuki;
    • Tanaka, Hisashi;
    • Inaba, Megumi;
    • Haruyama, Terunobu;
    • Nakamura, Junya;
    • Kishikawa, Takayuki;
    • Nakashima, Masanao;
    • Iwasa, Keiichi;
    • Fujiwara, Keiichi;
    • Kohyama, Tadashi;
    • Kuyama, Shoichi;
    • Miyazawa, Naoki
    Publication type:
    Article
    26
    27

    Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.

    Published in:
    British Journal of Cancer, 2018, v. 119, n. 5, p. 530, doi. 10.1038/s41416-018-0206-7
    By:
    • Aoki, Yoichi;
    • Ochiai, Kazunori;
    • Lim, Soyi;
    • Aoki, Daisuke;
    • Kamiura, Shoji;
    • Lin, Hao;
    • Katsumata, Noriyuki;
    • Cha, Soon-Do;
    • Kim, Jae-Hoon;
    • Kim, Byoung-Gie;
    • Hirashima, Yasuyuki;
    • Fujiwara, Keiichi;
    • Kim, Young-Tak;
    • Kim, Seok Mo;
    • Chung, Hyun Hoon;
    • Chang, Ting-Chang;
    • Kamura, Toshiharu;
    • Takizawa, Ken;
    • Takeuchi, Masahiro;
    • Kang, Soon-Beom
    Publication type:
    Article
    28
    29

    Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE‐826.

    Published in:
    Cancer Science, 2022, v. 113, n. 11, p. 3877, doi. 10.1111/cas.15479
    By:
    • Nishio, Shin;
    • Yonemori, Kan;
    • Usami, Tomoka;
    • Minobe, Shinichiro;
    • Yunokawa, Mayu;
    • Iwata, Takashi;
    • Okamoto, Aikou;
    • Aoki, Yoichi;
    • Itamochi, Hiroaki;
    • Takekuma, Munetaka;
    • Harano, Kenichi;
    • Yamamoto, Keiko;
    • Maruko, Takeshi;
    • Ugai, Hiroyuki;
    • Tekin, Cumhur;
    • Colombo, Nicoletta;
    • Fujiwara, Keiichi;
    • Hasegawa, Kosei;
    • Ushijima, Kimio
    Publication type:
    Article
    30
    31
    32
    33

    Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.

    Published in:
    Cancer Science, 2017, v. 108, n. 9, p. 1834, doi. 10.1111/cas.13307
    By:
    • Nishikawa, Tadaaki;
    • Matsumoto, Koji;
    • Tamura, Kenji;
    • Yoshida, Hiroyuki;
    • Imai, Yuichi;
    • Miyasaka, Aki;
    • Onoe, Takuma;
    • Yamaguchi, Satoshi;
    • Shimizu, Chikako;
    • Yonemori, Kan;
    • Shimoi, Tatsunori;
    • Yunokawa, Mayu;
    • Xiong, Hao;
    • Nuthalapati, Silpa;
    • Hashiba, Hideyuki;
    • Kiriyama, Tsukasa;
    • Leahy, Terri;
    • Komarnitsky, Philip;
    • Fujiwara, Keiichi
    Publication type:
    Article
    34

    Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2005, v. 131, n. 3, p. 147, doi. 10.1007/s00432-004-0626-z
    By:
    • Kozuki, Toshiyuki;
    • Fujimoto, Nobukazu;
    • Ueoka, Hiroshi;
    • Kiura, Katsuyuki;
    • Fujiwara, Keiichi;
    • Shiomi, Katsuhiko;
    • Mizobuchi, Koichi;
    • Tabata, Masahiro;
    • Hamazaki, Shuji;
    • Tanimoto, Mitsune
    Publication type:
    Article
    35

    Oxyphilic cell variant of endometrioid adenocarcinoma.

    Published in:
    Pathology International, 1998, v. 48, n. 9, p. 754, doi. 10.1111/j.1440-1827.1998.tb03978.x
    By:
    • Fukuoka, Keiko;
    • Hirokawa, Mitsuyoshi;
    • Shimizu, Michio;
    • Fujiwara, Keiichi;
    • Kohno, Ichiro;
    • Shintaku, Masayuki;
    • Manabe, Toshiaki
    Publication type:
    Article
    36
    37

    Integrated genomic/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin.

    Published in:
    Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-69796-4
    By:
    • Nishijima, Akira;
    • Oda, Katsutoshi;
    • Hasegawa, Kosei;
    • Koso, Takahiro;
    • Asada, Kayo;
    • Ikeda, Yuji;
    • Taguchi, Ayumi;
    • Maeda, Daichi;
    • Nagae, Genta;
    • Tsuji, Shingo;
    • Tatsuno, Kenji;
    • Uehara, Yuriko;
    • Kurosaki, Akira;
    • Sato, Sho;
    • Tanikawa, Michihiro;
    • Sone, Kenbun;
    • Mori, Mayuyo;
    • Ikemura, Masako;
    • Fujiwara, Keiichi;
    • Ushiku, Tetsuo
    Publication type:
    Article
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50